Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)

Tipranks - Tipranks - Sat Apr 11, 5:29AM CDT

In a report released today, Matthew Weston from UBS maintained a Hold rating on Novo Nordisk, with a price target of DKK332.00.

Easter Sale - 70% Off TipRanks

Weston covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, Sanofi, and AstraZeneca. According to TipRanks, Weston has an average return of 10.2% and a 69.00% success rate on recommended stocks.

Novo Nordisk has an analyst consensus of Hold, with a price target consensus of DKK294.54.

See Insiders’ Hot Stocks on TipRanks >>

0QIU market cap is currently DKK1058.1B and has a P/E ratio of 13.44.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.

Read More on GB:0QIU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).